Current therapeutic strategies of anti-HER2 treatment in advanced breast cancer patients
The HER2/neu ( ERBB2 ) oncogene is amplified and/or overexpressed in approximately 20% of breast cancers, and is a strong prognostic factor for relapse and poor overall survival, particularly in node-positive patients. It is also an important predictor for response to trastuzumab, which has establ...
| Main Authors: | , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2016-03-01
|
| Series: | Contemporary Oncology |
| Subjects: | |
| Online Access: | https://www.termedia.pl/Current-therapeutic-strategies-of-anti-HER2-treatment-in-advanced-breast-cancer-patients,3,27104,1,1.html |